Personalized microbiome-guided diet shows more durable benefit than low-FODMAP in IBS over 12 months

Nutrition Evidence: RCT · Multicenter open-label randomized controlled trial with blinded outcome assessment; 6-week dietary intervention followed by 12-month observational follow-up 2026-08-20

Gut health

A 12-month randomized trial compared a microbiome-guided personalized diet with the standard low-FODMAP diet in adults with irritable bowel syndrome. The personalized approach maintained symptom improvements long-term, while low-FODMAP benefits faded by month 12.

Both diets initially reduced IBS symptoms over 6 weeks, but their long-term trajectories diverged sharply. The personalized diet (PD) maintained an IBS Severity Scoring System (IBS-SSS) improvement of −78.3 points at 12 months, whereas the low-FODMAP diet (LFD) showed symptom regression, with scores rising +29.3 points by the same timepoint (between-group p = 0.001).

At 12 months, 62.5% of the personalized-diet group were symptom responders, compared with 34.5% in the low-FODMAP group—an absolute risk difference of 28 percentage points (95% CI 4.2–47.7). Quality of life and mood metrics (anxiety and depression scales) also favoured the personalized approach over the year. Gut microbiota profiling revealed that the personalized diet sustained gains in microbial diversity (Shannon alpha-diversity +0.205 at 12 months, p < 0.01), whereas the low-FODMAP diet did not show comparable durability. A modest compositional difference between diets at 6 months did not persist at 12 months. The authors note this is a hypothesis-generating study and call for larger trials to confirm whether personalized microbiome-guided approaches offer genuinely superior long-term outcomes in IBS management.

Takeaway

A microbiome-guided personalized diet may sustain IBS symptom relief longer than the low-FODMAP diet, though this remains preliminary and larger studies are needed.

The mechanism behind sustained PD benefit appears linked to maintenance of microbial diversity rather than a single composition signature—the between-group microbiota profile similarity was modest at 6 months and disappeared by 12 months, suggesting the PD's durability is not simply about preserving a specific bacterial community. Subgroup analysis and mechanistic drivers of divergence (e.g., whether personalization preserved more prebiotic substrates or reduced a narrowing effect) are not detailed, leaving the precise way PD protects against symptom relapse unclear. The trial was open-label (participants knew their group), which could introduce expectation bias, though outcome assessors were blinded to allocation. Baseline characteristics, adherence rates post-intervention, and reasons for symptom regression in LFD group are not provided in this summary, limiting our ability to isolate whether regression reflects diet cessation, natural IBS waxing, or specific harms of prolonged LFD restriction. The study explicitly frames itself as hypothesis-generating, not a definitive answer: larger, longer-term trials with mechanistic biomarkers and real-world adherence tracking would be needed to validate whether PD is truly superior or whether the benefit reflects selection, bias, or chance variation in this relatively small cohort.

Takeaway · Cadence

If you have IBS and have tried the low-FODMAP diet without sustained relief, you might explore whether a personalized approach—ideally guided by microbiome testing and a dietitian—could help maintain improvements after the initial dietary phase. Rather than abandoning dietary structure entirely after 6 weeks, consider working with a practitioner to refine your diet to your own microbiota profile and tolerances, since the rigid low-FODMAP approach may not suit everyone long-term. This is not a reason to stop a low-FODMAP diet if it's working for you now, but it does suggest that personalisation—adjusting foods based on your own gut signals and microbiome data—may be worth discussing with your care team.

Read the full breakdown in the app

The deeper explanation, the effect sizes and caveats, and what this means for your own sleep, exercise and reading — read it inside Cadence.

Open in Cadence →

References

Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial. — Gut microbes (Read the original)

#ibs #microbiome #personalized-diet #low-fodmap